black box warning for glp 1 agonists FDA Says to Drop Suicide From GLP-1 Drug Labels Researchers to explain the association
Description
In view of patient safety and preserve the science-based drug approval pathway, the FDA has issued a significant proposal regarding popular GLP-1 medications

In addition, this expert meeting does not take real-world evidence of GLP-1RAs use into consideration

(2004) 286:E6215

Other factors, such as participants health conditions, weight loss and metabolic improvements, may have influenced the results, researchers noted

The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand. Working Paper
